38821-49-7 Usage
Uses
Used in Parkinson's Disease Research:
Carbidopa is used as a dopa decarboxylase inhibitor for the research of Parkinson's disease. It prevents the conversion of levodopa to dopamine, thus reducing the peripheral adverse effects of levodopa and enhancing its effectiveness in treating Parkinson's disease.
Used in Pancreatic Cancer Research:
Carbidopa is used as an inhibitor of pancreatic cancer cell and tumor growth, providing a potential therapeutic approach for pancreatic cancer treatment.
Used as a Pharmaceutical Reference Standard:
Carbidopa may be used as a pharmaceutical reference standard for the determination of the analyte in pharmaceutical formulations by chromatography techniques, ensuring the quality and consistency of the drug in various applications.
Used in Drug Formulations:
Carbidopa is combined with levodopa for the treatment of Parkinson's disease and Parkinson's syndrome, providing a more effective and safer treatment option by reducing the peripheral conversion of levodopa to dopamine and minimizing side effects.
Check Digit Verification of cas no
The CAS Registry Mumber 38821-49-7 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 3,8,8,2 and 1 respectively; the second part has 2 digits, 4 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 38821-49:
(7*3)+(6*8)+(5*8)+(4*2)+(3*1)+(2*4)+(1*9)=137
137 % 10 = 7
So 38821-49-7 is a valid CAS Registry Number.
InChI:InChI=1/C10H14N2O4.H2O/c1-10(12-11,9(15)16)5-6-2-3-7(13)8(14)4-6;/h2-4,12-14H,5,11H2,1H3,(H,15,16);1H2
38821-49-7Relevant articles and documents
Asymmetric Synthesis of L-carbidopa based on a highly enantioselective α-amination
Pericas, Lex,Shafir, Alexandr,Vallribera, Adelina
supporting information, p. 1448 - 1451 (2013/06/27)
A stereoselective synthesis of l-carbidopa in seven steps and 50% overall yield from commercial compounds is described. The key step involves a highly enantioselective α-amination reaction of an acyclic β-ketoester with di-tert-butyl azodicarboxylate indu
Pharmaceutical compositions containing an effervescent acid-base couple
-
, (2008/06/13)
A pharmaceutical composition in the form of effervescent tablets comprising an active ingredient and an effervescent blend, comprising an acidic component and sodium glycine carbonate as alkaline components. Preferred acid components are fumaric acid, maleic acid, and their salts. Tablets are prepared in normal thermohygrometric conditions and with standard tabletting equipment. A pre-granulation process is also disclosed.
Dual release formulation comprising levodopa ethyl ester and a decarboxylase inhibitor in immediate release layer with levodopa ethyl ester and a decarboxylase inhibitor in a controlled release core
-
, (2008/06/13)
A tablet which comprises: an inner core formulated for controlled release comprising a mixture of (a) a granulated admixture of a decarboxylase inhibitor and a surfactant, and (b) levodopa ethyl ester or a derivative or a pharmaceutically acceptable salt
